Pharma Mar (PHMMF) News Today $88.18 0.00 (0.00%) As of 05/1/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Exploring High Growth Tech Stocks in Europe April 2025April 14, 2025 | finance.yahoo.comPharma Mar’s Credit Rating Maintained at ‘BB+’April 4, 2025 | tipranks.comPharma Mar Implements Share Delivery Plan to Boost Employee EngagementApril 2, 2025 | tipranks.com3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings GrowthMarch 27, 2025 | finance.yahoo.comPharma Mar, S.A. (OTCMKTS:PHMMF) Short Interest Up 43.4% in FebruaryPharma Mar, S.A. (OTCMKTS:PHMMF - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 32,700 shares, an increase of 43.4% from the February 13th total of 22,800 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 327.0 days. Currently, 0.2% of the shares of the stock are short sold.March 17, 2025 | marketbeat.comPharma Mar (OTCMKTS:PHMMF) Reaches New 12-Month High - Time to Buy?Pharma Mar (OTCMKTS:PHMMF) Reaches New 1-Year High - Here's What HappenedMarch 4, 2025 | marketbeat.comPharma Mar Releases 2024 Director Remuneration ReportFebruary 28, 2025 | tipranks.comHigh Insider Ownership Growth Companies To Watch In February 2025February 21, 2025 | finance.yahoo.comHigh Growth Tech Leads These 3 Top Stocks with PotentialFebruary 11, 2025 | finance.yahoo.comPharma Mar And 2 Other Stocks That May Be Trading Below Estimated ValueFebruary 4, 2025 | uk.finance.yahoo.comPharma Mar (OTCMKTS:PHMMF) Reaches New 52-Week High - Here's WhyPharma Mar (OTCMKTS:PHMMF) Sets New 52-Week High - Here's WhyJanuary 28, 2025 | marketbeat.com3 Growth Stocks With Insider Ownership Expecting Up To 71% Earnings GrowthJanuary 23, 2025 | finance.yahoo.com3 Stocks Estimated To Be Up To 48% Below Intrinsic ValueJanuary 6, 2025 | finance.yahoo.comInsider-Led Growth Stocks To Watch In December 2024December 25, 2024 | sg.finance.yahoo.comPharma Mar S.A. Reduces Share Capital by Canceling SharesNovember 22, 2024 | markets.businessinsider.comPharma Mar Achieves Legal Win in Aplidin CaseNovember 21, 2024 | markets.businessinsider.comPharma Mar Hits $10 Million Milestone with JanssenNovember 5, 2024 | msn.comNew miRNA inhibitor could extinguish the 'inflammatory fire' that stroke causes in the brainOctober 29, 2024 | msn.comPHMMF Pharma Mar, S.A.October 10, 2024 | seekingalpha.comPharma Mar (OTCMKTS:PHMMF) Trading 31.1% Higher Pharma Mar (OTCMKTS:PHMMF) Stock Price Up 31.1%August 29, 2024 | marketbeat.comChemists develop modular approach for creating important class of pharmaceutical compoundsJuly 19, 2024 | msn.comRevolutionizing Pharmaceutical Manufacturing: The Visionary Work of Tejesh MarsaleMay 18, 2024 | markets.businessinsider.comTransforming Pharmaceutical Manufacturing: The Visionary Work of Tejesh MarsaleMay 16, 2024 | msn.comPharming Group’s Strong Performance and Growth Prospects Justify Buy RatingMarch 18, 2024 | markets.businessinsider.comMar-a-lagoMarch 16, 2024 | newsweek.comPersica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back painMarch 7, 2024 | markets.businessinsider.comPharma Mar SAU (PHMR)February 17, 2024 | investing.comPfizer’s 2024 Comeback: A Dividend Gem in the Pharma MarketFebruary 1, 2024 | investorplace.comTwo new databases combine computer science and pharmaceutical researchJanuary 9, 2024 | msn.comFirst West Africa Healthcare, Lab, & Pharma Week 2024 To Hold In NigeriaNovember 29, 2023 | msn.comPharma Mar SA PHMNovember 6, 2023 | morningstar.comPiramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024October 28, 2023 | markets.businessinsider.comPharma Mar S.A.July 15, 2023 | barrons.comYifan PharmaceuticalJune 21, 2023 | forbes.comPHM.MC - Pharma Mar, S.A.June 6, 2023 | finance.yahoo.comNEEDHAM & COMPANY INC. Maintains Pharma Mar (XMAD:PHM) Buy RecommendationApril 22, 2023 | msn.comPharmaceutical Excipients Market Top Players By 2031March 27, 2023 | marketwatch.comPharmaceutical company to open in McHenryMarch 25, 2023 | news.yahoo.comInnate Pharma (IPHA) Receives a Buy from H.C. WainwrightMarch 24, 2023 | markets.businessinsider.comBig Pharma companies back new startup out of Mass General BrighamMarch 16, 2023 | bizjournals.comPiramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2023November 9, 2022 | markets.businessinsider.comEuropean Commission suspects pharma group Teva broke antitrust rulesOctober 10, 2022 | yahoo.comPharmacists Database List of Emails, Phone Numbers, Contact InformationAugust 30, 2022 | apnews.comLife Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variantsJanuary 11, 2022 | finance.yahoo.comPharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in TaiwanNovember 11, 2021 | finanznachrichten.deSpain's PharmaMar posts 58% drop in 9-mth profit despite higher revenuesOctober 28, 2021 | news.yahoo.comSpain's PharmaMar nine-month net profit falls 58%October 28, 2021 | reuters.comSpain's PharmaMar sales rise on demand for cancer treatmentsJuly 29, 2021 | nasdaq.com Get Pharma Mar News Delivered to You Automatically Sign up to receive the latest news and ratings for PHMMF and its competitors with MarketBeat's FREE daily newsletter. Email Address PHMMF Media Mentions By Week PHMMF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHMMF News Sentiment▼-1.000.83▲Average Medical News Sentiment PHMMF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHMMF Articles This Week▼10▲PHMMF Articles Average Week Get Pharma Mar News Delivered to You Automatically Sign up to receive the latest news and ratings for PHMMF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HTCMY News LEGIF News OMRNY News JEXYY News DSRLF News HNLGY News ISMAY News HKMPF News SHNWF News SQNXF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PHMMF) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma Mar, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharma Mar With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.